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Abstract
Background: Pakistan ranks 7th globally in terms of tuberculosis (TB) disease burden (incidence 181/100000 pop./yr;
prevalence of 329/pop./yr). Reports from different populations show variable associations of TB susceptibility and severity
with cytokine gene polymorphisms. Tuberculosis clinical severity is multi-factorial and cytokines play a pivotal role in the
modulation of disease severity. We have recently reported that the ratio of two key cytokines (IFNc and IL10) show
significant correlation with the severity spectrum of tuberculosis. The objective of the current study was to analyze the
frequency of cytokine gene polymorphisms linked to high and low responder phenotypes (IFNc +874 ThiRAlo and IL10
21082 GloRAhi) in tuberculosis patients.
Methods and Findings: Study groups were stratified according to disease site as well as disease severity: Pulmonary N= 111
(Minimal, PMN=19; Moderate, PMD= 63; Advance, PAD= 29); Extra-pulmonary N= 67 (Disseminated DTB= 20, Localized
LTB = 47) and compared with healthy controls (TBNA= 188). Genotype analyses were carried out using amplification
refractory mutation system-PCR (ARMS-PCR) and stimulated whole blood (WB) culture assay was used for assessing cytokine
profiles. Our results suggest that the IFNc +874 TT genotype and T allele was overrepresented in PMN (p= 0.01) and PMD
(p= 0.02). IFNc +874 TT in combination with IL10 GGlo genotypes showed the highest association (x2 = 6.66, OR = 6.06, 95%
CI = 1.31–28.07, p= 0.01). IFNc AAlo on the other hand in combination with IL10 GGlo increased the risk of PAD (OR= 5.26;
p = 0.005) and DTB (OR= 3.59; p = 0.045).
Conclusion: These findings are consistent with the role of IL10 in reducing collateral tissue damage and the protective role
of IFNc in limiting disease in the lung.
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Introduction
Pakistan ranks 7th globally in terms of tuberculosis disease
burden with an incidence of 181/100000 pop./yr and a
prevalence of 329/ pop. /yr. Several reports from different
countries have shown that household contacts of active pulmonary
tuberculosis are at much higher risk of latent infection that range
from 30–80% depending on the intensity of tuberculosis disease
transmission [1–4]. Only ten percent of those latently infected
individuals develop TB disease during their lifetime [5]. Identifi-
cation of these high-risk individuals in recently exposed/ infected
individuals is of great importance to TB Control Programs for
reducing the disease burden in the community. Association of
pathological severity with increased circulating levels of different
pro-inflammatory and or down-regulatory cytokines in tuberculo-
sis is fairly well established [6]. An increasing number of studies
have shown that single nucleotide polymorphisms (SNPs) located
in the promoter or coding regions of cytokine genes result in
differential cytokine secretion due to altered transcriptional
activation. In humans, families with SNPs in IFNc receptor 1
[7,8] genes have shown Mendelian susceptibility to tuberculosis.
Single nucleotide polymorphisms (SNPs) located in the first intron
of the IFNc gene (at position +874) have shown variable
associations with tuberculosis disease susceptibility and severity
[9]. IFNc (+874ThiRAlo) polymorphism is located within a
putative NF-kb binding site and shows preferential binding to
the T allele and correlates with high IFNc producer phenotype
[10]. Similarly polymorphisms in IL10 [11] linked to high and low
producer phenotypes have shown conflicting associations with
tuberculosis disease susceptibility and disease severity in different
patient populations [12,13]. This is not surprising as, although
IFNc may be a key cytokine in activation of macrophages for
mycobacterial stasis and killing [14], disease severity outcomes in
tuberculosis depend on the balance among several different
cytokines in situ, depending on the disease site. IL10 is particularly
important in reducing collateral tissue damage, particularly in the
lung by dampening macrophage activation and by indirectly
antagonizing IFNc function [15]. We have recently reported that
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the ratio of these two key cytokines (IFNc/IL10) shows significant
correlation with clinical severity in extra-pulmonary tuberculosis
[16],with higher IFNc/IL10 ratio relating to less severe disease.
We have now extended these studies to analyze the frequency of
high and low responder cytokine phenotypes (IFNc +874 ThiRAlo
and IL10 21082 GloRAhi) to analyze the relationship of these
SNPs with clinical severity of tuberculosis. Our results show that
SNPs in IFNc are significantly related to site of TB disease
(Pulmonary vs. Extrapulmonary) while combinations of SNPs in
IFNc and IL10 genes are important determinants of TB disease
severity. Our results therefore substantiate our aim of the study.
Results
Demographic characteristics of the study groups
There were no significant differences in age in TBNA and TBA
groups (Table 1). The ratio of females was significantly higher
(p,0.05) in TBA compared to TBNA. However, no significant
association of genotype with age or sex was observed in both TBA
and TBNA (.0.05) using multiple logistic regression analysis (data
not shown).
Relationship of genotype and phenotype of IFNc
(+874ThiRAlo) and IL10 (21082 GloRAhi) in TBNA
Figure 1 shows the relationship of cytokine secretion in response
to mycobacterial antigen stimulation with different genotypes
IFNc (+874 ThiRAlo) and IL10 (21082 GloRAhi).We found IFNc
TT and IL10 AA to be the high producer phenotype in response to
mycobacterial antigens. We next looked at the frequency of these
genotypes in association with disease severity.
Distinct IFNc +874 but not IL10 21082 genotype SNPs
are associated with different disease sites and not with
TB susceptibility
Cytokine genotypes and alleles frequencies in all patient groups
were compared with healthy controls (Tables 3 & 4). IFNc
+874TRA genotype distribution was in Hardy-Weinberg equilib-
rium for both patients and controls (TBA; p=0.607 and TBNA;
p=1.0). On the other hand, IL-10 21082GRA polymorphism
showed deviation from HWE due to excess of heterozygosity (TBA
and TBNA; p=0.00004). Cases and controls were compared using
x2, odds ratios (OR) and their confidence intervals, (95% CI). A p
value of ,0.05 was considered significant. Different cytokine
genotypes and alleles showed distinct associations with different
disease types as described below.
IFNc +874 TT genotype showed significant association with
PTB (x2 = 6.05, p=0.034) (Table 3). This association was
restricted to the T allele (Table 4). In terms of disease severity in
the lung this association was restricted to PMN and PMD and was
not seen with PAD. Similarly, no association was observed with
ETB or stratified ETB on the basis of disease severity (DTB vs.
LTB). When we compared healthy controls with latent infection
(TST+) similar and much more marked effect of IFNc +874 TT
genotype was observed (Table 3). Therefore, genotype associations
were not only different according to disease site (PTB vs. ETB) but
there was a distinct difference between severity within a disease site
(PMD vs. PAD). These results therefore suggest that it is
inappropriate to pool tuberculosis patient with differing sites and
even severity within individual sites.
Table 3 also shows the frequency of IL10 21082 genotype in
relation to disease site as well as disease severity. Neither IL10
21082 genotype nor alleles (Table 4) show any association in
relation to either site or severity of tuberculosis. The p values were
similar when patients were compared with TST+ controls
(Table 4). There was an overrepresentation of the IL10 21082
heterozygous genotype GA in both controls and PTB as well as
ETB. Linkage disequilibrium is not uncommon in consangious
populations such as where the study is being conducted. [17]
Table 1. Demographic characteristics of TB Patients and
Controls.
Group Studied N Gender Age (years)
Female (%) Male (%) Mean Range
TB not affected controls
(TBNA)
188 88 (46.8) 100 (53.1) 28.10 6–70
TB affected patients (TBA) 188 118 (62.7) 70 (37.2) 33.40 7–81
Pulmonary TB (PTB) 111 65 (58.5) 46 (41.4) 32.0 10–81
Pulmonary minimal (PMN) 19 9 (47.3) 10 (52.6) 36.3 15–81
Pulmonary moderate (PMD) 63 37 (58.7) 26 (41.2) 33.0 13–70
Pulmonary advance (PAD) 29 19 (65.5) 10 (34.4) 26.2 10–69
Extra pulmonary TB (ETB) 67 47 (70.1) 20 (35.0) 34.5 7–80
Disseminated TB (DTB) 20 12 (60.0) 8 (40.0) 37.3 16–80
Localized TB (LTB) 47 35 (74.5) 12 (25.5) 33.3 7–75
Note: Patient stratification is as given in Materials and Methods. Abbreviations
for groups are given in brackets. TBA included 10 previously treated patients.
doi:10.1371/journal.pone.0004778.t001
Figure 1. Relationship of IFNc and IL10 SNPs with mycobacte-
rial antigen induced cytokine secretion. Whole blood from TB not
affected (TBNA) Tuberculin skin test positive donors was stimulated
with M. tuberculosis culture filtrate (CF) proteins [5 mg/ml] and
supernatants tested at 2 days for IL10 secretion and day 5 for IFNc
secretion using ELISA method as described in material and methods.
Results are expressed as pg/ml after deducting secretion in un-
stimulated whole blood.
doi:10.1371/journal.pone.0004778.g001
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Multiloci genotype association with risk of disease
severity across the tuberculosis disease spectrum
We have previously shown that IFNc/IL10 ratio is a critical
determinant of disease severity [16]. Since both cytokines (IFNc,
IL10) showed distinct associations with different sites and severity
of TB, we also assessed if genotype combinations for these two
cytokines may contribute to increased risk of TB with respect to
site or severity. There were nine possible combinations. Only
significant results are shown in Table 5. As expected from previous
analyses (Table 3) there was a clear association of IFNc TThi with
pulmonary disease while IFNc AAlo was clearly associated with
increased risk of PAD and DTB. The effect of IL10 genotype
combination was much more evident with disease site rather than
disease severity. IL10 GGlo in combination with IFNc AAlo was
associated with the highest risk for DTB (OR=3.59; p=0.045).
The results were similar when cases were compared with TST+
controls.
Discussion
Although the effect of cytokine gene polymorphisms (SNPs) on
tuberculosis disease sites or disease severity have been reported in
different populations, our results for the first time show differential
association of cytokine genotype combinations with either
pulmonary or extra-pulmonary disease. We also report that in
the lung compartment the high responder IL10 21082 AAhi may
play a critical role in limiting tissue damage in PTB. Because of
careful characterization of disease in each of the group, we are
able to show significant differences between groups and among
groups. In addition, differences seen in both cytokines SNPs can be
reconciled with their biological function. We feel that this is a very
important issue despite small numbers in the stratified groups.
When pulmonary patients are not stratified the sample size is
sufficient for power of statistics. We have therefore given results for
both pooled and stratified groups. There are very few studies,
which relate genotype to phenotype. This is the strength of the
current study.
There are considerable variations in allelic frequencies of
cytokine gene polymorphisms in different populations [18] and
therefore it is not surprising that genetic polymorphisms associated
with tuberculosis have yielded conflicting results in different ethnic
groups [19]. IFNc polymorphism (+874 ThiRAlo) is the most
studied polymorphism in terms of association with tuberculosis
disease sites and severity. However, the reports are conflicting in
that A allele is more common in patients with TB and T alleles,
more common in controls in Italian [20], South African [21] Hong
Kong Chinese [22]and Spanish populations [23]. In Turkey, one
study reported no association [24], while a later study in the same
population showed an association with the A allele [25]. In Croatia
[26] an association with A allele was found only in microscopy and
culture positive vs. negative TB patients. On the other hand, no
association has been reported in Caucasians in Houston, Texas
[27] and South Indian populations [28]. There is only one study in
Colombia [29] where an association of IFNc +874 T allele with
the more localized pleural disease has been observed. Our results
are in agreement with the latter study. We show that the effect of
IFNc T allele in TB affected patients is restricted to pulmonary
patients with minimal/ moderate disease increasing the risk by 2–3
folds (Table 4). Both our study and the Colombian study show a
much more marked association with the more protective form of
tuberculosis. Some of the differences could be due to the influence
of other genes linked to tuberculosis disease susceptibility
[10,28,30–32]. As shown in our study, the presence of high
responder IL10 21082 AAhi may limit lung tissue damage when
associated with IFNc TThi. Turner has reported AA to be a low
producer phenotype in response to mitogenic (ConA) stimulus
[33]. Mycobacterial antigens are potent stimulators of macro-
phages [34] while Con A is primarily a T cell stimulator [33].
Therefore, it is possible that different stimuli may result in
differential transcription of the same gene. For the current study
we considered mycobacterial antigens to be the more appropriate
stimulus.
A similar discrepancy is observed with IL10 (21082 GloRAhi)
where no associations were reported in Gambian [35], Korean
[36] and Spanish [23] populations. An association of A allele was
observed in Italian (Sicilian) [37] population, and GA heterozy-
gosity was associated with pulmonary TB in Cambodia [38]. Our
results indicate that the homozygous GGlo increases the risk of
DTB when it is associated with IFNc +874 AAlo phenotype
(OR=3.59; p = 0.045). This is consistent with the low levels of
mycobacterial stimulated IFNc and IL10 from DTB [39]. We
have observed an overrepresentation of GA heterozygous genotype
in our study groups and may increase the risk of PMN when
associated with IFNc AAlo (Table 5). The frequency of GA
heterozygosity is highly variable in different populations ranging
from 82.5% in Iranian population to 5% in Singapore Chinese
[18]. Our results (70.2%) are closer to the Iranian population
frequency. We further confirmed PCR amplified product by
sequencing which also gave the expected SNP sequences for both
IFNc and IL10 genotypes. Therefore, it is difficult to attribute the
inflation in GA heterozygosity to artifacts in genotyping method-
ology as most studies have reported widely differing frequencies
using ARMS PCR [18]. It is not unexpected to find linkage
disequilibrium in consangious population such as the setting in
which this study was conducted [17]. Further population-based
studies are needed to address this issue.
Nevertheless, a consensus seems to be emerging in that the
combined effect of several cytokine SNPs may play a more crucial
role in disease severity [29]. These results also substantiate our
earlier report [16] that IFNc/IL10 ratio may be the critical
determinant of clinical severity in both pulmonary and extra-
pulmonary tuberculosis. A meta analyses recently published
reinforces the critical importance of IFNc +874 T/A as a genetic
marker for TB resistance [9], while IL10 indeed had some specific
effect on TB determining the disease form and severity and not
with susceptibility per se. Our results are consistent with these
findings.
If the rationale for analyzing cytokine gene polymorphism is to
understand the pathogenesis of human disease, to identify
potential markers of susceptibility or disease severity, responder
vs. non-responders in therapeutic and vaccine trials, and to design
novel strategies for intervention in high-risk groups, then the
diversity of genetic associations warrants that such analyses are
carried out in indigenous population. Our results further highlight
the importance of stratification of patients in relation to disease
severity, which otherwise mask the significance of associations in
combined groups.
Materials and Methods
Subject studied
Gene polymorphisms were analyzed in 376 donors (TB not
affected, TBNA=188 and TB affected, TBA=188). Table 1
shows the breakdown of TB patients in terms of clinical severity:
WHO guidelines for disease classification for non HIV related
tuberculosis was adopted [16,40] as follows. DTB (N=20) had
involvement of two or more sites with primary focus as meninges
(N= 3), spinal (N=1), intestinal (N= 11), splenic (N= 3) or miliary
Gene Polymorphisms in TB
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(N= 4) with or without lung involvement. PTB (N=111) had
involvement of lung parenchyma exclusively. LTB (N=47)
included TB restricted to one site without lung involvement
(lymph nodes = 29, peripheral joints = 9, pleural = 8 and endo-
bronchial = 1). Patients were included in the study if they were
positive by one or more of the following criteria: microscopy,
culture, histology, imaging (chest6rays for pulmonary patients and
miliary involvement, CT scans for abdominal and skeletal and
splenic involvement, MRI for meninges, or definitive clinical
response (Table 2).
The control group consisted of healthy donors (TBNA=188)
with no signs, symptoms or history of previous tuberculosis.
Tuberculin skin tests (TST) positivity was assessed by administer-
ing five tuberculin units intracutaneously on the volar surface of
the right arm. An induration of $10 mm was used as a cut for
positive responses (TST+) which is considered to be indicative of
latent infection. The Aga Khan University Ethical Review
Committee (ERC) approved the project. Written consent was
obtained, for each participant or his or her guardians in case of
minors after explaining the purpose of the study.
DNA Extraction
Five ml blood were collected in ACD (VWR Scientific, West
Chester, PA, USA) tubes and kept frozen until use. Genomic DNA
was extracted from frozen whole blood using Promega Wizard
Genomic DNA Purification Kit (Promega Corporation Madison,
WI, USA) according to the manufacturer’s instructions. After
extraction, DNA was quantified by spectrophotometery, checked
for purity and stored at 235uC until further analyses.
Molecular analysis
IFNc and IL10 genotype analyses were carried out using
amplification refractory mutation system-PCR (ARMS-PCR) [41].
Primers used for the detection of SNPs were purchased from
MWG-Biotech AG, (Ebersberg, Germany). Human growth
hormone and b actin were used as internal controls to check the
accuracy of PCR reactions. Amplified products were monitored by
electrophoresis on agarose gel containing 10 mg/ml ethidium
bromide. Product bands were visualized on a transiluminator and
polaroid pictures were taken for interpretation.
Table 2. Diagnostic modality used for confirmation of tuberculosis.
Disease* category N % (TST$10 mm) Microscopy Culture Histology "Imaging
Response to
treatment
TBNA 188 71 - - - - -
Pulmonary 111 62 47 24 0 38 2
Disseminated 20 35 1 3 2 12 2
Localized 47 43 1 10 13 10 13
Note: Primary diagnostic modality used diagnosis of tuberculosis.
*Criteria for disease category given in material and methods.
"Imaging tests included chest6rays for pulmonary patients, CT scan and or MRI for disseminated disease.
doi:10.1371/journal.pone.0004778.t002
Table 3. Genotype frequencies in healthy controls and different clinical forms of tuberculosis (TB).
Genotypes TBNA (188) TBA (188) PTB (111) PMN (19) PMD (63) PAD (29) ETB (67) DTB (20) LTB (47)
IFN-c (+874)
TT 25 (13.3) 39 (20.74) 27 (24.32) 8 (42.11) 16 (25.4) 3 (10.34) 12 (17.91) 3 (15.00) 9 (19.15)
TA 87 (46.28) 83 (44.15) 47 (42.34) 6 (31.58) 28 (44.44) 13 (44.83) 30 (44.78) 8 (40.00) 22 (46.80)
AA 76 (40.43) 66 (35.11) 37 (33.33) 5 (26.32) 19 (30.16) 13 (44.83) 25 (37.31) 9 (45.00) 16 (34.04)
x2 3.86 6.05 10.69 5.58 0.30 0.87 0.29 1.28
Corrected p= 0.08 0.034 0.012 0.029 0.588 0.433 0.859 0.278
Corrected p= TBNA TST+ (133) 0.064 0.007 0.029 0.008 0.780 0.649 0.857 0.495
IL-10 (21082)
GG 20 (10.64) 27(14.36) 19 (17.12) 4 (21.05) 7 (11.1) 8 (27.59) 8 (11.94) 4 (20.00) 4 (8.51)
GA 136 (72.34) 132 (70.21) 71 (63.96) 11 (57.893) 46(73.02) 14 (48.25) 51 (76.12) 12 (60.00) 39 (82.98)
AA 32 (17.02) 29 (15.43) 21 (18.92) 4 (21.05) 10 (15.89) 7 (24.14) 8 (11.94) 4 (20.00) 4 (8.51)
x2 1.25 3.09 2.20 0.05 8.41 0.98 1.85 2.52
Corrected p= 0.33 0.489 0.621 0.831 0.374 0.384 0.612 0.437
Corrected p= TBNA TST+ (133) 0.435 0.767 0.945 0.867 0.341 0.330 0.582 0.357
Note: Patient stratification is given in Materials and Methods. N for each group given in brackets. Abbreviations used as in Table 1. Number (frequency) of genotypes is
indicated. Pearson chi analysis was carried to determine the significance of differences.
All significant p values are indicated in bold. P approaching significance is given in italics. p,0.05 is considered significant.
doi:10.1371/journal.pone.0004778.t003
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Sequencing methodology was used as a second confirmatory
method on a subset of samples to verify that correct alleles were
being identified by ARMS-PCR. The primers used for sequencing
analyses were IFNc Forward (59-TAT GAT TCT GGC TAA
GGA-39), IFNc Reverse (59-CCC CAA TGG TAC AGG TTT
CT-39) and IL-10 Forward (59-TGT GGA AGG GGA AGG TG-
39), IL-10 Reverse (59-TAA AAG ATG GGG TGG AAG AA-39).
These primers were designed using software Lasergene version 7.0
(DNAstar, Madison, WI, USA) and amplify a part of the gene that
covers IFNc (+874TRA) or IL10 (21082GRA) SNPs to yield
products size of 318 and 329 bp respectively. PCR products were
purified with the QIAquick PCR purification kit (Qiagen, Hilden,
Germany) according to the manufacturer’s instructions. Purified
products were then sent to Macrogen for sequencing (Macrogen
Inc, Seoul, Korea) with both forward and reverse primers.
Sequencing results were analyzed by BLAST search of the
GenBank database and EMBOSS pairwise alignment of the
EMBL-EBI database. There was complete concordance between
PCR based and sequence based analyses for homozygous as well
as heterozygous genotypes (+874, TT=13; AA=9; 21082,
GG=6; GA=17).
Whole blood stimulation assays
Stimulated whole blood (WB) culture assay for assessing
cytokine profiles have been described in detail previously [34].
Briefly, heparinized blood was diluted 1/11 with sterile RPMI
1640 tissue culture medium containing 100 units/ml of penicillin/
100 mg/ml streptomycin and 2 mM L-glutamine (Sigma Chem-
ical Co., St Louis, Mo). Diluted WB (900 ml/ well) were stimulated
with MTB culture filtrate proteins [5 mg/m] in a 24-well tissue
culture plates (Flow Laboratories, Irvine, Scotland) within 2 hours
of collection. Supernatants were collected from the wells at varying
intervals and stored as 46200 ml aliquots at 235uC.
Cytokine assessment
Cytokine (IFNc and IL10) in supernatants were assessed using
pairs of monoclonal antibodies as described in detail previously
[39]. Dose response curves were set up in each individual plate.
Supernatants were serially diluted and optical density readings in
the linear range of the dose response curve were used for
calculating the concentrations. The final concentrations (pg/ml)
were obtained after multiplying the values by dilutions at which
the OD was read. The sensitivity and range of cytokine detection
was 7.5–1000 pg/ml and was comparable to that reported by the
manufacturer.
Statistical Analysis
Allelic and genotypic frequencies and multi loci analysis were
compared for all groups together and for individual patient and
control groups. Computer software SPSS version 16.0 and Epi
Info 2000 applications were used to carry out statistical analyses.
Frequencies were compared between groups by Pearson chi-
squared tests or Fisher’s exact tests, when analyzing allelic
frequencies lower than five to determine statistical significance
differences between groups. Odds ratios (OR) with respective
confidence intervals (95% CI) for disease susceptibly were also
calculated. Linear-by-linear test were used to determine the
significance (corrected p values) of genotypes between TB groups
and healthy controls. Multiple logistic regression analysis was
applied, to determine the effect of age and sex with genotypes.
Values of p,0.05 were considered significant for both Pearson and
linear-by-linear x2 test. Hardy-Weinberg proportions were
determined by applying the equation (p2+2pq+q2).
Table 4. Differences in allele frequencies in healthy controls and tuberculosis patients
IFN-c (+874 ThiRAlo) N chi-value corrected p= OR 95% CI (lower) 95% CI (upper)
TBNA 188
TBA 188 3.20 0.074 1.31 0.79 1.75
PTB 111 4.78 0.029 1.46 1.04 2.04
PMN 19 6.72 0.01 2.4 1.22 4.72
PMD 63 4.95 0.026 1.59 1.05 2.38
PAD 29 0.29 0.587 0.85 0.47 1.53
ETB 67 0.46 0.50 1.15 0.77 1.72
DTB 20 0.032 0.858 0.94 0.47 1.86
LTB 47 1.12 0.274 1.29 0.82 2.05
IL-10 (21082 GloRAhi)
TBNA 188
TBA 188 0.53 0.48 1.11 0.83 1.48
PTB 111 0.29 0.58 1.01 0.79 1.54
PMN 19 0.14 0.708 1.14 0.58 2.22
PMD 63 0.025 0.875 1.03 0.69 1.55
PAD 29 0.49 0.486 1.22 0.7 2.12
ETB 67 0.036 0.85 1.04 0.7 1.54
DTB 20 0.15 0.701 1.14 0.59 2.18
LTB 47 0.307 0.58 1.14 0.72 1.79
Note: Patient stratification is given in material and methods. N for each group is given in brackets. Abbreviations used as in Table 1.
doi:10.1371/journal.pone.0004778.t004
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AA/AA % 8.51 0 3.17 13.79 15 2.13
chi2 4.71
corrected p= 0.03
OR 0.21
(95% CI) (0.04–0.98)
AA/GA % 39.26 15.79 22.2 17.24 20 29.7
chi2 4.85 4.06
corrected p= 0.028 0.044
OR 0.45 0.50
(95% CI) (0.24–0.93) (0.25–0.99)
doi:10.1371/journal.pone.0004778.t005
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